Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.
hepatocellular carcinoma
lenvatinib
ramucirumab
regorafenib
sorafenib
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
10
07
2020
revised:
30
07
2020
accepted:
02
08
2020
entrez:
15
12
2020
pubmed:
16
12
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Currently, there is no molecular-targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u-HCC after progression on treatment with LEN. A total of 13 patients with u-HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3% (2/13) and 69.2% (9/13), respectively. According to RECIST, the ORR and DCR were 0% (0/13) and 69.2% (9/13), respectively. The median progression-free survival was 4.1 months. The median albumin-bilirubin scores did not deteriorate significantly at 4, 6, and 8 weeks after initiation of SOR, compared with the scores at the baseline. The most frequent grade 1 or 2 adverse events (AEs) were palmar-plantar erythrodysesthesia, fatigue, diarrhea, and hypertension. There was no incidence of grade 3 AEs. Treatment with SOR may be effective for u-HCC after failure on LEN and may not worsen the liver reserve.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Currently, there is no molecular-targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u-HCC after progression on treatment with LEN.
METHODS PATIENTS AND RESULTS
UNASSIGNED
A total of 13 patients with u-HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3% (2/13) and 69.2% (9/13), respectively. According to RECIST, the ORR and DCR were 0% (0/13) and 69.2% (9/13), respectively. The median progression-free survival was 4.1 months. The median albumin-bilirubin scores did not deteriorate significantly at 4, 6, and 8 weeks after initiation of SOR, compared with the scores at the baseline. The most frequent grade 1 or 2 adverse events (AEs) were palmar-plantar erythrodysesthesia, fatigue, diarrhea, and hypertension. There was no incidence of grade 3 AEs.
CONCLUSION
CONCLUSIONS
Treatment with SOR may be effective for u-HCC after failure on LEN and may not worsen the liver reserve.
Identifiants
pubmed: 33319048
doi: 10.1002/jgh3.12408
pii: JGH312408
pmc: PMC7731817
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1135-1139Informations de copyright
© 2020 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
J Clin Oncol. 2009 Apr 10;27(11):1800-5
pubmed: 19255312
Int J Cancer. 2008 Feb 1;122(3):664-71
pubmed: 17943726
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Anticancer Res. 2020 Apr;40(4):2089-2093
pubmed: 32234901
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Can J Gastroenterol. 2013 Jul;27(7):393-6
pubmed: 23862169
Clin Cancer Res. 2008 Sep 1;14(17):5459-65
pubmed: 18765537
Hepatol Res. 2019 Sep;49(9):1054-1065
pubmed: 31033165
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
J Gastroenterol Hepatol. 2019 Jun;34(6):1066-1073
pubmed: 30549320
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Dig Dis. 2014;32(6):733-9
pubmed: 25376291
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Hepatol Res. 2019 Jan;49(1):111-117
pubmed: 30144256
PLoS One. 2015 Sep 30;10(9):e0138776
pubmed: 26421430
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Oncotarget. 2020 Jun 30;11(26):2531-2542
pubmed: 32655838
Dig Dis. 2015 Oct;33(6):765-70
pubmed: 26488173
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Anticancer Res. 2019 Sep;39(9):5149-5156
pubmed: 31519627
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Invest New Drugs. 2015 Dec;33(6):1257-62
pubmed: 26462681
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Hepatol Res. 2020 Mar;50(3):374-381
pubmed: 31721363